1439 related articles for article (PubMed ID: 22453568)
21. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Joensuu H; Eriksson M; Hall KS; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Ballman KV; Leinonen M; DeMatteo RP; Reichardt P
Cancer; 2014 Aug; 120(15):2325-33. PubMed ID: 24737415
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
Eisenberg BL; Harris J; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M
J Surg Oncol; 2009 Jan; 99(1):42-7. PubMed ID: 18942073
[TBL] [Abstract][Full Text] [Related]
23. Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
Izquierdo ME; Bonastre MT
Anticancer Drugs; 2012 Jun; 23 Suppl():S7-9. PubMed ID: 22739668
[TBL] [Abstract][Full Text] [Related]
24. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
25. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
[TBL] [Abstract][Full Text] [Related]
26. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
Li J; Gong JF; Wu AW; Shen L
Eur J Surg Oncol; 2011 Apr; 37(4):319-24. PubMed ID: 21277730
[TBL] [Abstract][Full Text] [Related]
27. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
28. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2012; 17(7):992-7. PubMed ID: 22643537
[TBL] [Abstract][Full Text] [Related]
29. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Blanke CD; Demetri GD; von Mehren M; Heinrich MC; Eisenberg B; Fletcher JA; Corless CL; Fletcher CD; Roberts PJ; Heinz D; Wehre E; Nikolova Z; Joensuu H
J Clin Oncol; 2008 Feb; 26(4):620-5. PubMed ID: 18235121
[TBL] [Abstract][Full Text] [Related]
30. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
[TBL] [Abstract][Full Text] [Related]
31. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
Gronchi A; Bonvalot S; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom HJ; van Coevorden F; Penel N; Kopp HG; Duffaud F; Goldstein D; Broto JM; Wardelmann E; Marréaud S; Smithers M; Le Cesne A; Zaffaroni F; Litière S; Blay JY; Casali PG
JAMA Surg; 2020 Jun; 155(6):e200397. PubMed ID: 32236507
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal stromal tumors: who should get imatinib and for how long?
Balachandran VP; DeMatteo RP
Adv Surg; 2014; 48(1):165-83. PubMed ID: 25293614
[TBL] [Abstract][Full Text] [Related]
33. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Verweij J; Casali PG; Zalcberg J; LeCesne A; Reichardt P; Blay JY; Issels R; van Oosterom A; Hogendoorn PC; Van Glabbeke M; Bertulli R; Judson I
Lancet; 2004 Sep 25-Oct 1; 364(9440):1127-34. PubMed ID: 15451219
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.
Kanda T; Nishida T; Wada N; Kobayashi O; Yamamoto M; Sawaki A; Boku N; Koseki M; Doi T; Toh Y; Kakeji Y; Sugiyama T; Komatsu Y; Kikuchi S; Ogoshi K; Katai H; Miyachi K; Hirota S; Ohtsu A
Int J Clin Oncol; 2013 Feb; 18(1):38-45. PubMed ID: 22105894
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Wang D; Zhang Q; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M; Eisenberg BL
Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182
[TBL] [Abstract][Full Text] [Related]
36. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
Koh Y; Lee HE; Oh DY; Kim JH; Lee SH; Kim SH; Kim DW; Im SA; Kim TY; Heo DS; Kim WH; Bang YJ
Jpn J Clin Oncol; 2012 Nov; 42(11):1020-7. PubMed ID: 22952296
[TBL] [Abstract][Full Text] [Related]
37. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
38. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E
PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912
[TBL] [Abstract][Full Text] [Related]
39. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
Rutkowski P; Magnan H; Chou AJ; Benson C
BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655
[TBL] [Abstract][Full Text] [Related]
40. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]